PharmaMar announces that its second most advanced marine-derived antitumor agent, Aplidin, has commenced Phase II clinical trials in both prostate and bladder cancers.
In the Pipeline
- PharmaMar announces that its second most advanced marine-derived antitumor agent, Aplidin, has commenced Phase II clinical trials in both prostate and bladder cancers.
- TheraQuest Biosciences has announced that the FDA Office of Orphan Products Development has granted orphan drug designation for TQ-1017, the company’s abuse deterrent once-daily extended-release tramadol for the treatment of HIV-associated neuropathy.
- Icagen has initiated enrollment in its pivotal Phase III trial of ICA-17043 for the treatment of sickle cell disease.
- Human Genome Sciences has completed the enrollment and initial dosing of patients in a Phase II clinical trial of mapatumumab (HGS-ETR1) in patients with advanced colorectal cancer.
- Oncolytics Biotech has received clearance from the FDA to begin a Phase I/II clinical trial to investigate the use of Reolysin, its proprietary formulation of the human reovirus, to treat patients with recurrent malignant gliomas.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.